wp header logo 57

Worldwide Internet of Medical Things (IoMT) Industry is Expected to Grow at a 24.6% CAGR Between 2022 to 2028: Innovation and Adoption of New IoMT Devices Drives Growth – Yahoo Finance

Breaking News Trending

Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) — The “Global Internet of Medical Things (IoMT) Market Research and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The global market for IoMT is projected to have a considerable CAGR of around 24.6% during the forecast period.
The IoMT is a collection of medical devices and applications connected to healthcare IT systems via online computer networks in which data can be exchanged among other devices without requiring human-to-human or human-to-computer interaction.
These devices are used to improve healthcare quality while reducing the cost and time. Various IoMT applications in hospitals and clinics involve patient monitoring, X-ray machines, CT scans, and smart apps used to connect patients and doctors at remote places.
In the medical device industry, major growth has been observed as IoT based medical technology has been adopted widely in developed economies. The innovation of new IoMT devices and the adoption of these devices in healthcare organizations on large scale owing to the increasing need for patients’ outcomes are the major factors driving the growth of the market. On the other hand, the large adoption of electronic health records (EHR) has been another major factor driving the market growth.
Besides, high costs of IoT based medical devices along with lack of skilled professionals towards IOT technology act as major restraints for the market growth.
The reason behind the high cost is the requirement of the installation of software, hardware, training fees, networking infrastructure, & IT support. Moreover, increasing technological advancement supported by start-ups and rising demand for point of care medical devices is expected to drive the market growth during the forecast period.
COVID-19 Impact on the global IoMT Market
The global IoMT market is positively hit by the impact of the COVID-19 pandemic. The increase in the number of patients affected with many diseases including coronavirus has increased the demands and use of IoMT devices to increase the patient outcomes and to monitor and maintain the data related to patient medication, this led to an increase in market growth.
Segmental Outlook
The global IoMT market is segmented based on component, application, and end-user. Based on component, the market is categorized into medical devices, and software & services. Based on application, the market is classified into patient monitoring, telemedicine, connected imaging, drug development, and others.
Among these, the use of IoMT devices in the patient monitoring segment is expected to grow significantly during the forecast period. As these devices are coupled with advanced technology through which patient diagnosis and medication can be monitored through smart devices from remote locations. The IoMT market based on end-user divided into hospitals & clinics, research institutes & academics, and homecare.
Hospitals and Clinics further projected to dominate the global IoMT market
Based on end-users, the hospitals, and clinics segment projected to dominate the market during the forecast period. As the use of IoMT device in healthcare sectors are gaining popularity in the last few years. The IoMT devices find their applications in patient monitoring, telemedicine, connected imaging, drug development, among others.
The advantages provided by IoMT devices such as real-time monitoring, improved drug management, improved patient outcomes, and a reduction in medical expenditure are making them more demand in healthcare sectors.
Thus, hospitals and clinics are the largest end-users of these devices. More than 70% of the organization use the IoMT to maintain and record the data related to the patients. The increasing advancements in these technologies and growing healthcare sectors coupled with IoMT devices are expected to increase the market growth.
Regional Outlook
Geographically, the global IoMT market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)).
Among these, Asia-Pacific is expected to be the fastest growing region during the forecast period owing to rising digitalization in the healthcare sector and increasing adoption of EHR in emerging countries. The rise in disposable income, increase in awareness regarding technological advancement in IoMT devices, and increasing demand for better patient outcomes are the major factors driving regional growth.
North America is estimated to dominate the global IoMT Market
Geographically, North America dominated the global IoMT market in 2020, and it is expected to grow with a significant CAGR during the forecast period. The well-established healthcare infrastructure and IT industry is the factor that drives the market growth.
The high prevalence of the chronic disease has increased the use of IoMT devices in the region, and new launches in IoMT by major players are expected to boost the market during the forecast period. Besides, the increase in R&D expenditure and technological advancements are the factors that are also fueling the market prospects in the region.
Market Players Outlook
The key players in the global IoMT market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Apple, Inc., Boston Scientific Corp., IBM Corp., Cisco Systems, Inc., GE Healthcare, Koninklijke Philips N.V., Medtronic PLC, Siemens Healthcare GmbH, among others.
These market players adopt different marketing strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions to generate more revenue and to remain competitive in the market. For instance, in February 2021, Hillrom announced the acquisition of contact-free continuous monitoring technology from EarlySense. The deal was done for $30 million. The acquisition will aid Hillrom to build a differentiated suite of connected solutions with EarlySense’s next-generation AI-based sensing technologies specifically for remote patient care and to improve patient outcomes.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global Internet of Medical Things (IoMT) market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying ‘who-stands-where’ in the market.
Key Topics Covered:

1. Report Summary

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid on key players

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global IOMT MARKET, By Component
5.1.1. Medical Devices
5.1.2. Software and Services
5.2. Global IOMT MARKET, By Application
5.2.1. Patient Monitoring
5.2.2. Telemedicine
5.2.3. Connected Imaging
5.2.4. Drug Development
5.2.5. Others (Fitness and Wellness Measurement)
5.3. Global IOMT MARKET, By End-User
5.3.1. Hospitals and Clinics
5.3.2. Research Institutes and Academics
5.3.3. Homecare

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Russia
6.2.7. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korean
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East& Africa

7. Company Profiles
7.1. Adheretech, LLC
7.2. AliveCor, Inc.
7.3. Apple, Inc.
7.4. BioSerenity SAS
7.5. Boston Scientific Corp.
7.6. Carre Technologies Inc.
7.7. CenTrak, Inc.
7.8. Cisco Systems, Inc.
7.9. Cue Health Inc.
7.10. EarlySense, Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/4p7h4f-internet?w=12
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Shares of apparel company Hanesbrands (NYSE: HBI) dropped like a rock on Thursday after the company provided lackluster financial guidance and announced some substantial pivots to management's priorities. As of 11:40 a.m. ET, Hanesbrands stock was down 23% — particularly painful, considering the market is soaring today. On one hand, fourth-quarter revenue of $1.47 billion beat guidance from Hanesbrands' management.
Investors got a reminder of the capabilities of Palantir Technologies' (NYSE: PLTR) products, helping to reinforce the bull case for the stock. Palantir came to market in late 2020 to great enthusiasm, based largely on the reputation of its technology. The data-analytics provider is credited with helping the Pentagon find Osama bin Laden and with flagging the Bernie Madoff Ponzi scheme.
Shares of Eli Lilly (NYSE: LLY) are tumbling Thursday morning. Ahead of the opening bell, Lilly announced its 2022 fourth-quarter financial results. Thanks to high expectations for newer growth products like Mounjaro and the steady progress of top clinical assets like Alzheimer's treatment donanemab, investors bid up the big pharma stock by a whopping 32.4% over the course of 2022.
When Cathie Wood speaks, people listen. The chief executive of Ark Investment Management has had a far-from-perfect record when it comes to her investment choices — not to mention not exactly flattering feedback from CNBC's Jim Cramer. When asked what stock Wood would choose she won a million dollar lottery and was forced to choose a stock for ten years, Wood's pick was just as disruptive as her reputation.
The Nasdaq Composite dipped into a bear market last year, and the tech-heavy index is still 28% off its high. Investors often overreact to good and bad news, so stocks tend to rise too high during bull markets and fall too far during bear markets. Warren Buffett hinted at that quirk of human nature when he said, "Be fearful when others are greedy, and be greedy when others are fearful."
Taseko Mines Limited (TSX: TKO) (NYSE American: TGB) (LSE: TKO) ("Taseko" or the "Company") is pleased to announce it has entered into an agreement to extend the maturity date of its US$50 million Revolving Credit Facility (the "Facility") by an additional year to July 2, 2026. The Facility, which is arranged and fully underwritten by National Bank of Canada ("National Bank"), is currently undrawn and available for general and working capital purposes.
Top health insurance company Humana (NYSE: HUM) wasn't necessarily tops with investors on Wednesday. After reporting its latest set of quarterly figures, the company's share price bumped slightly higher, by 0.3%, which wasn't high enough to beat the S&P 500 index's more than 1% increase. It's not that Humana's results for the fourth quarter 2022 were bad or uninspiring; it's just that they didn't excel.
Despite a dismal performance in 2022, shares of all-digital bank SoFi Technologies (NASDAQ: SOFI) climbed 50.3% in January. There are lots of reasons for the run-up, not least of which were a better-than-expected performance during the fourth quarter of 2022 and an improved outlook. Will the big gains SoFi made in January fizzle out in February, or is the stock at the beginning of a much longer bull run?
What happened SoFi Technologies (NASDAQ: SOFI) was good to investors in January as its stock price soared 50.3% higher, according to data provided by S&P Global Market Intelligence. As of Feb. 2, after a few more good days since the end of the month, it is up a whopping 75% year to date.
Yahoo Finance Live’s Julie Hyman breaks down oil earnings.
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.
Yahoo Finance’s Ines Ferre joins the Live show to discuss how AI stocks are trading amid the ChatGPT hype. 
General Mills (GIS) closed at $77.99 in the latest trading session, marking a -0.47% move from the prior day.
Did you know that if a company were to increase its dividends by 5% per year, it would take 14 years for its payouts to double? A couple of stocks with the most aggressive dividend growth records you can invest in today are UnitedHealth Group (NYSE: UNH) and Broadcom (NASDAQ: AVGO). Health insurance giant UnitedHealth Group may not strike income investors as an ideal dividend stock to buy, as it yields just under 1.4%, which is below the S&P 500's current average yield of 1.7%.
Pfizer (NYSE: PFE) enjoyed a record year in 2022. The big drugmaker's revenue topped $100 billion. Its earnings per share soared 42% to $5.47, which translates to nearly $31.4 billion in profits. Both top- and bottom-line numbers set all-time highs.
Dividend investors should consider loading up on these stocks as this could be a good year for both of their businesses.
Shares of Amazon (NASDAQ: AMZN) were moving higher today, even though there was no major news out on the tech giant. With Amazon's earnings report due out after the market closes today, investors are hoping it can benefit from similar tailwinds. As of 12:11 p.m. ET, Amazon stock was up 6.2%, while Meta stock was up nearly 25%.
Following the company's previous earnings release, Cramer apologized to his audience, saying that his trust in Meta's management team was "ill-advised" and that his bullish hubris was "extraordinary, and I apologize."
The company failed to pay more than $28 million in interest payments on three tranches of notes due Feb. 1.
The mean of analysts' price targets for Alibaba (BABA) points to a 31.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.


Leave a Reply

Your email address will not be published. Required fields are marked *